CEO Schaffer’s Insider Buy Signals Big Upside for Cingulate’s Biotech Future
CEO Shane Schaffer’s bulk buy of 6,809 Cingulate shares and warrants signals strong confidence in the biopharma’s upcoming milestones—could spark a rally.
4 minutes to read